8/9/24 16:30 | 8/7/24 | GLYC | Health | Drug | Pharmaceutical Preparations | Invus Public Equities, L.P. | NY | T | | S.m | -61 | 0.1899 | 0 | -322 | -5 | 6,318 | D | | | | | | | | | | | | | | |
8/7/24 16:30 | 8/5/24 | GLYC | Health | Drug | Pharmaceutical Preparations | Invus Public Equities, L.P. | NY | T | | S.m | -41 | 0.1870 | 0 | -220 | -3 | 6,640 | D | | | | | | | | | | | | | | |
8/5/24 16:53 | 8/1/24 | GLYC | Health | Drug | Pharmaceutical Preparations | Invus Public Equities, L.P. | NY | T | | S.m | -71 | 0.2033 | 0 | -350 | -5 | 6,860 | D | | | | | | | | | | | | | | |
7/30/24 17:16 | 7/26/24 | GLYC | Health | Drug | Pharmaceutical Preparations | Invus Public Equities, L.P. | NY | T | | S.m | -315 | 0.2286 | 0 | -1,379 | -16 | 7,210 | D | | | | | | | | | | | | | | |
5/18/23 16:27 | 5/17/23 | GLYC | Health | Drug | Pharmaceutical Preparations | Hahn Brian M. | MD | O | SVP Fina | S | -7 | 1.95 | 0 | -4 | -7 | 53 | D | | | | | | | | | | | | | | |
1/27/23 17:15 | 1/25/23 | GLYC | Health | Drug | Pharmaceutical Preparations | Sandell Scott D | MD | T | | S.m | -11,485 | 3.14 | 0 | -3,652 | -42 | 4,968 | I | | | | | | | | | | | | | | |
1/6/23 18:35 | 1/5/23 | GLYC | Health | Drug | Pharmaceutical Preparations | Sandell Scott D | MD | T | | S | -197 | 2.76 | 0 | -71 | -1 | 8,620 | I | | | | | | | | | | | | | | |
1/4/23 17:26 | 12/30/22 | GLYC | Health | Drug | Pharmaceutical Preparations | Sandell Scott D | MD | T | | S.m | -1,186 | 2.98 | 0 | -398 | -4 | 8,691 | I | | | | | | | | | | | | | | |
3/10/22 17:06 | 3/9/22 | GLYC | Health | Drug | Pharmaceutical Preparations | Magnani John L. | MD | O | SVP of R | S | -4 | 1.09 | 0 | -3 | -1 | 326 | D | | | | | | | | | | | | | | |
3/10/22 17:05 | 3/9/22 | GLYC | Health | Drug | Pharmaceutical Preparations | Girard Armand | MD | O | SVP,Chie | S | -3 | 1.09 | 0 | -2 | -9 | 23 | D | | | | | | | | | | | | | | |
3/10/22 17:03 | 3/9/22 | GLYC | Health | Drug | Pharmaceutical Preparations | Hahn Brian M. | MD | O | SVP Fina | S | -3 | 1.09 | 0 | -3 | -7 | 37 | D | | | | | | | | | | | | | | |